Navigating the Evolving Landscape of Breast Cancer Monoclonal Antibodies: Strategic Intelligence for 2026 Decision-Making The global market for breast cancer monoclonal antibodies stands at a pivotal inflection point. With a projected compound annual growth rate of 7.5% from 2026 through 2032, this therapeutic segment is poised to deliver substantial clinical and commercial impact. As...